Dive Brief:
- Aspen Neuroscience could be the first company of its kind to go public in the U.S. if it follows through on newly disclosed plans to join the Nasdaq.
- Founded in 2018, Aspen hopes to treat Parkinson’s disease by taking a patient’s own cells and reprogramming them so that they eventually become dopamine-producing neurons. Dopamine is essential for fluid body movement, muscle control and coordination. Parkinson’s degrades and ultimately destroys cells that produce this molecule. Aspen’s most advanced therapy — known as sasineprocel or ANPD001 — has gone through an early-stage clinical trial and is now entering late-stage testing.
- While other neurology-focused cell therapy developers have gone public, Aspen may be the first built around a treatment specifically targeting Parkinson’s. The company has raised approximately $347 million since its inception, and intends to trade under the ticker symbol “ASPE.”
Dive Insight:
Like Aspen’s programs, many cell therapies in development are designed to be one-time treatments made with cells donated from the patient. These medicines have already shown powerful effects in certain cancers as well as early signs that they could be useful against autoimmune conditions like lupus.
However, they are also complex, expensive and difficult to make. Aspen’s production process takes roughly four months. It starts with harvesting a skin sample, which is then sent off to a manufacturing facility where select cells are isolated and grown. They are then engineered into “induced pluripotent stem cells,” which can become any type of cell.
Scientists then, through a highly technical set of procedures, introduce a series of molecules and proteins that effectively guide these cells to become durable, “precursor” cells that mature into dopamine-producing neurons. The best batches are frozen and shipped back to treatment centers, where they’re surgically implanted into the patient.
This intensive process isn’t cheap. In 2025, Aspen recorded a net loss of $62 million, and over the first six months of this year that figure reached almost $37 million. Research and development accounts for more than 70% of Aspen’s operating expenses.
In registration documents filed Oct. 9, Aspen noted that, based on its current operating plan, its existing cash, cash equivalents and marketable securities won’t be enough to keep operating for another year. “Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern,” the company wrote. Even with a successful public offering, Aspen believes that it will need “substantial additional capital” to finance itself.
Aspen’s announcement does come at a time when the window for biotech initial public offerings is more open than it’s been in years. Two dozen biotechs have gone public so far in 2026, a pace not seen since 2021. Among the new cohort, 16 raised at least $250 million from their offerings, according to BioPharma Dive data.
There is also a healthy backlog of drugmakers in the IPO queue, including a pair of immune system specialists — Bambusa Therapeutics and Lycia Therapeutics — that submitted registration documents this month. Two other biotechs, City Therapeutics and Iambic Therapeutics, are scheduled to price offerings this week as well.
